NO20006027D0 - Anvendelse av indigofargestoff-bisindolderivater til fremstillingen av et medikament for å hemme cyclinavhengige kinaser - Google Patents
Anvendelse av indigofargestoff-bisindolderivater til fremstillingen av et medikament for å hemme cyclinavhengige kinaserInfo
- Publication number
- NO20006027D0 NO20006027D0 NO20006027A NO20006027A NO20006027D0 NO 20006027 D0 NO20006027 D0 NO 20006027D0 NO 20006027 A NO20006027 A NO 20006027A NO 20006027 A NO20006027 A NO 20006027A NO 20006027 D0 NO20006027 D0 NO 20006027D0
- Authority
- NO
- Norway
- Prior art keywords
- medicament
- manufacture
- dependent kinases
- indigo dye
- inhibiting cyclin
- Prior art date
Links
- 108091007914 CDKs Proteins 0.000 title abstract 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 title abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 title 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 title 1
- 101150012716 CDK1 gene Proteins 0.000 abstract 2
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 abstract 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 1
- 101100495314 Caenorhabditis elegans cdk-5 gene Proteins 0.000 abstract 1
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 abstract 1
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98109845A EP0966963A1 (en) | 1998-05-29 | 1998-05-29 | Use of indigoid bisindole derivatives as CDK1 inhibitors |
| EP99105693 | 1999-03-19 | ||
| PCT/EP1999/003625 WO1999062503A2 (en) | 1998-05-29 | 1999-05-26 | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20006027D0 true NO20006027D0 (no) | 2000-11-28 |
| NO20006027L NO20006027L (no) | 2001-01-22 |
Family
ID=26149292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006027A NO20006027L (no) | 1998-05-29 | 2000-11-28 | Anvendelse av indigoid-bisindolderivater til fremstilling av et medikament for å hemme cyclinavhengige kinaser |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1079826B1 (no) |
| JP (1) | JP2002516851A (no) |
| KR (1) | KR20010078722A (no) |
| AT (1) | ATE233560T1 (no) |
| AU (1) | AU762830B2 (no) |
| BR (1) | BR9910810A (no) |
| CA (1) | CA2333661A1 (no) |
| DE (1) | DE69905712T2 (no) |
| DK (1) | DK1079826T3 (no) |
| ES (1) | ES2194468T3 (no) |
| HU (1) | HUP0102240A3 (no) |
| IL (1) | IL139914A0 (no) |
| NO (1) | NO20006027L (no) |
| WO (1) | WO1999062503A2 (no) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| AU775633B2 (en) * | 1999-04-12 | 2004-08-05 | Heinz Herbert Fiebig | Use of cell membrane penetrating indigoid bisindole derivatives |
| EA200101046A1 (ru) * | 1999-04-12 | 2002-04-25 | Герхард Айзенбранд | Производные индигоидных бис-индолов |
| AU2002213132A1 (en) * | 2000-10-10 | 2002-04-22 | Board Of Regents, The University Of Texas System | Suppression of cyclin kinase activity for prevention and treatment of infections |
| DE10053474A1 (de) * | 2000-10-24 | 2002-05-02 | Schering Ag | Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung |
| DE10061162A1 (de) * | 2000-11-30 | 2002-07-11 | Schering Ag | Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung |
| WO2002059123A2 (en) * | 2000-12-18 | 2002-08-01 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds |
| FR2821358B1 (fr) * | 2001-02-27 | 2006-04-07 | Aventis Pharma Sa | Oxindoles inhibiteurs de cdk-1 et leur application en therapeutique |
| DE10114138C2 (de) * | 2001-03-16 | 2003-03-27 | Schering Ag | Cdk-inhibitorische Indirubinderivate mit erhöhter Löslichkeit |
| DE10125763A1 (de) * | 2001-05-17 | 2002-11-28 | Schering Ag | Verwendung selektiver Indirubinderivate als VEGF-R Inhibitoren |
| DE10129028A1 (de) * | 2001-06-11 | 2003-01-02 | Schering Ag | Lösliche Cdk-inhibitorische Indirubinderivate |
| TW201041580A (en) * | 2001-09-27 | 2010-12-01 | Alcon Inc | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| US7582670B2 (en) | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
| US6566341B1 (en) * | 2001-12-13 | 2003-05-20 | Natrogen Therapeutics, Inc. | Derivative of isoindigo, indigo and indirubin for the treatment of cancer |
| US20050154046A1 (en) | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| CA2469649C (en) * | 2001-12-13 | 2011-05-03 | Natrogen Therapeutics, Inc. | Derivatives of isoindigo, indigo and indirubin and use in treating cancer |
| CA2481036C (en) * | 2002-04-03 | 2012-05-29 | Allergan, Inc. | (3z)-(3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors |
| CN1199946C (zh) * | 2002-10-29 | 2005-05-04 | 无锡杰西医药科技有限公司 | 一种特异性吲哚类化合物及制备方法与其在治疗和预防癌症等疾病中的应用 |
| KR100588803B1 (ko) * | 2004-01-27 | 2006-06-12 | 학교법인조선대학교 | 암세포주에 항암활성을 지닌 인디루빈 유도체 |
| WO2005107466A1 (en) * | 2004-05-12 | 2005-11-17 | Bayer Cropscience Gmbh | Plant growth regulation |
| MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
| CN1329376C (zh) * | 2005-09-19 | 2007-08-01 | 无锡杰西医药科技有限公司 | 一种n(1)-烃基-3′-肟基靛玉红衍生物(i)的制备方法及其医学应用 |
| JP4587961B2 (ja) * | 2006-01-16 | 2010-11-24 | 独立行政法人科学技術振興機構 | 神経因性疼痛治療剤 |
| EP2379549B1 (en) | 2008-12-22 | 2016-09-21 | Eisenbrand, Gerhard | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| EP2199292A1 (en) | 2008-12-22 | 2010-06-23 | Technische Universität Kaiserlautern | 7-azaindirubins, 7'-azaindirubins, 7-7'-diazaindirubin and the corresponding 3'-oxime ether derivates: production thereof, their production and use as a medicament |
| FR2945747A1 (fr) | 2009-05-25 | 2010-11-26 | Centre Nat Rech Scient | Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire |
| FR2952818B1 (fr) * | 2009-11-23 | 2013-05-31 | Oreal | Composition contenant au moins un precurseur de coloration derive d'indole, au moins un colorant indoline dione et au moins un compose organique liquide |
| KR101180030B1 (ko) * | 2010-02-05 | 2012-09-05 | 광주과학기술원 | 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체 |
| US8524121B2 (en) * | 2012-01-27 | 2013-09-03 | Xerox Corporation | Bi-indoline-dithione polymers |
| CA2868302A1 (en) | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| CN103333161B (zh) * | 2013-05-28 | 2015-09-30 | 滁州市洛达生物科技有限公司 | 1’-氧代靛玉红的制备和用途 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| CN113773243B (zh) * | 2021-09-01 | 2023-01-06 | 大连理工大学 | 一种有机催化氧化吲哚自缩合制备异靛蓝类化合物的方法 |
| CN118317948A (zh) | 2021-10-08 | 2024-07-09 | 阿佐拉治疗股份有限公司 | 芳烃受体激动剂的衍生物 |
| CN115925610B (zh) * | 2022-12-05 | 2025-04-04 | 天津中医药大学 | 6,6'-二异戊烯基靛玉红及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS617254A (ja) * | 1984-06-20 | 1986-01-13 | Isukura Sangyo Kk | ビスインドリノンおよびそれを主成分とする制癌剤 |
| DE69734521T9 (de) * | 1996-08-23 | 2006-12-07 | Sugen, Inc., South San Francisco | Kombinatorische indolinonbibliotheken und verwandte produkte und verfahren zur behandlung von erkrankungen |
-
1999
- 1999-05-26 AT AT99926420T patent/ATE233560T1/de not_active IP Right Cessation
- 1999-05-26 HU HU0102240A patent/HUP0102240A3/hu unknown
- 1999-05-26 WO PCT/EP1999/003625 patent/WO1999062503A2/en not_active Ceased
- 1999-05-26 KR KR1020007013499A patent/KR20010078722A/ko not_active Ceased
- 1999-05-26 EP EP99926420A patent/EP1079826B1/en not_active Expired - Lifetime
- 1999-05-26 DE DE69905712T patent/DE69905712T2/de not_active Expired - Fee Related
- 1999-05-26 ES ES99926420T patent/ES2194468T3/es not_active Expired - Lifetime
- 1999-05-26 AU AU43687/99A patent/AU762830B2/en not_active Ceased
- 1999-05-26 DK DK99926420T patent/DK1079826T3/da active
- 1999-05-26 BR BR9910810-0A patent/BR9910810A/pt not_active IP Right Cessation
- 1999-05-26 JP JP2000551759A patent/JP2002516851A/ja active Pending
- 1999-05-26 IL IL13991499A patent/IL139914A0/xx unknown
- 1999-05-26 CA CA002333661A patent/CA2333661A1/en not_active Abandoned
-
2000
- 2000-11-28 NO NO20006027A patent/NO20006027L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002516851A (ja) | 2002-06-11 |
| KR20010078722A (ko) | 2001-08-21 |
| HUP0102240A2 (hu) | 2001-11-28 |
| DE69905712T2 (de) | 2004-01-29 |
| EP1079826A2 (en) | 2001-03-07 |
| WO1999062503A3 (en) | 2000-01-27 |
| AU4368799A (en) | 1999-12-20 |
| ATE233560T1 (de) | 2003-03-15 |
| DK1079826T3 (da) | 2003-06-23 |
| ES2194468T3 (es) | 2003-11-16 |
| IL139914A0 (en) | 2002-02-10 |
| CA2333661A1 (en) | 1999-12-09 |
| NO20006027L (no) | 2001-01-22 |
| HUP0102240A3 (en) | 2003-05-28 |
| AU762830B2 (en) | 2003-07-03 |
| BR9910810A (pt) | 2001-02-13 |
| EP1079826B1 (en) | 2003-03-05 |
| DE69905712D1 (de) | 2003-04-10 |
| WO1999062503A2 (en) | 1999-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20006027D0 (no) | Anvendelse av indigofargestoff-bisindolderivater til fremstillingen av et medikament for å hemme cyclinavhengige kinaser | |
| NO20014728L (no) | Derivater av pyrimido[6,1-a]isokinolin-4-on | |
| WO1999057117A3 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
| ATE401314T1 (de) | Benzodiazepin-derivate als gamma-secretase inhibitoren | |
| ATE309223T1 (de) | Cyclin-abhängige kinase inhibitoren | |
| TR200101860T2 (tr) | Sikline bağlı kinaz inhibitörleri olarak 4-alkenil (ve alkinil) oksidoller | |
| EE04432B1 (et) | Kinaase ja tsükliin/CDK komplekse inhibeerivad asendatud indolinoonid | |
| BR0108394A (pt) | Inibidores de cinase de proteìna de 2-indolinona de pirrol substituìdo | |
| MXPA03010810A (es) | Pirimidinas inhibidoras de cdk, su obtencion y su uso como medicamentos. | |
| ATE219765T1 (de) | Indolderivate als cgmp-pde inhibitoren | |
| MX9201419A (es) | Derivados de benzo isoxazol-piperidina. | |
| AR023542A1 (es) | Pirazolbenzodiazepinas | |
| AR022665A1 (es) | Compuestos farmaceuticamente activos | |
| MY116124A (en) | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug | |
| DE69835241D1 (de) | 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen | |
| DE60142469D1 (de) | Imidinderivate als antineoplastika | |
| BR0213185A (pt) | Derivados de 3-[4-(heterociclila substituìda)-pirrol-2-ilmetilideno]2-indolinona como inibidores de cinase | |
| TR199900503T2 (xx) | 3-�kameli pirido $4',3':4,5]thieno $2,3-D] pirimidin-t�revleri, elde edili�leri ve kullan�mlar�. | |
| TR200103237T2 (tr) | İmidazodiazepin türevi | |
| PL375697A1 (en) | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors | |
| BR9811091A (pt) | Derivado de 3,4,5,7-tetraidropirrol [3', 4':4,5] tieno[2,3-d]pirimidina 3-substituìdo, composto, e, uso do mesmo | |
| WO1998049146A3 (en) | Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer | |
| TR200103169T2 (tr) | 1,5-Benzodiazepin türevleri | |
| ECSP003706A (es) | Compuestos farmaceuticamente activos | |
| ECSP003445A (es) | Pirazolbenzodiazepinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |